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Patients with stoma evaluated their life quality only with 42.33 points from the 
overall 80. ConClusions: Patients with intestinal diseases are defatigable, and 
have abdominal problems frequently. In case of ulcerative colitis the burden of 
disease is higher, life quality is less favourable. Stoma negatively affects life qual-
ity. The residence is significantly affected by the disease burden and quality of life.
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anD The TreaTmenT InITIaTIon from a PhysIcIan’s & PaTIenT’s PoInT 
of VIew. fIrsT InTerIm analysIs of TurkIsh DaTa from mosaIc sTuDy 
(an InTernaTIonal mulTIcenTer ProsPecTIVe obserVaTIonal sTuDy 
To eValuaTe The ePIDemIoloGy, humanIsTIc anD economIc ouTcomes 
ofTreaTmenT for chronIc hePaTITIs c VIrus)
Koksal I1, Aladag M2, Koklu S3, Sezgin O4
1Karadeniz Tech University, Trabzon, Turkey, 2Inonu University, Malatya, Turkey, 3Hacettepe 
University, Ankara, Turkey, 4Mersin University, Mersin, Turkey
objeCtives: Chronic Hepatitis C Virus (HCV) infection negatively impacts the 
patient’s quality of life. Interferon (IFN) based therapy has been the standard of 
care for many years yet antiviral therapy of HCV has rapidly evolved since the 
introduction of direct acting antivirals (DAA). This report is based on Turkish Mosaic 
Study. The objective is to characterize patients with chronic HCV and assess the 
impact of IFN-containing treatment on health related quality of life, work related 
productivity and activities of daily living and health care utilization. Methods: 
MOSAIC is an international prospective multicenter observational study that is 
conducted in 20 countries. Consecutive patients with chronic HCV who initiated an 
IFN based treatment within 12 weeks were followed for 48 weeks. Patient charac-
teristics, co-morbidities, treatment history, HCV genotype and clinical status were 
recorded. The response type recorded for previous treatment as null response, 
relapse, discontinued and partial response. Results: Ninety one of 152 patients 
were treatment naïve, and the 61 were treatment experienced. Relapse was the 
dominating response type (50%). GT1 patient ratio was 65,8%, non GT1 patient was 
5,9%, and 28% of patients were unknown at the date of the report. 42.8% of patients 
were male, the mean age was 55.1 . The physicians have not recommended treat-
ment for 73.6% of patiens, and 16.4% of patients rejected the treatment. The leading 
reasons for physicians and the patients were “waiting for IFN-free treatment option” 
is followed by “presumed tolerabilty issue”. ConClusions: IFN based therapy 
has been the standard of care for CHC infection for many years yet the antiviral 
treatment paradigm of HCV has rapidly evolved since the introduction of IFN-free 
direct acting antivirals. Higher efficacy with less side effects seems to improving 
the standard of care.
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objeCtives: This is the first study to assess the diagnostic and therapeutic man-
agement of moderate-to-severe IBS-C in six European countries (France, Germany, 
Italy, Spain, Sweden and UK). Here we present the diagnosis and management 
results from Germany. Methods: Observational 12-month study (6 months ret-
rospective and 6 months prospective) in patients diagnosed with IBS-C (Rome-III 
criteria) in the last five years and moderate-to-severe disease severity at inclusion 
(IBS-Symptom Severity Scale (IBS-SSS) score ≥ 175). One of the main objectives was 
to determine healthcare resource utilisation (HRU) and costs prior to and after 
an active phase of the disease. Results: 102 patients were included (43% severe, 
mean age [±SD] 47.6±18.1 years old, 83.3% female). Mean time since diagnosis: 
4.6±8.4 years; mean symptom duration: 15.0±16.9 years. Diagnostic procedures 
since the onset of symptoms were highly variable: the most common were colo-
noscopies(78.4%), blood tests (65.7%), and abdominal ultrasounds(62.7%). The main 
associated comorbidities were insomnia(31.4%), hypertension(28.4%), chronic pain 
(27.5%), depression(27.5%), and gastroesophageal reflux disease (GERD; 27.5%). 
66.7% of patients had an average of 4.0±2.5 diagnostic tests during follow-up and 
71.6% took prescription drugs (54.9% for IBS-C). The most common medication 
groups were laxatives (35.6%), prokinetics (23.3%), antispasmodics (15.1%), and 
analgesics (11.0%). Overall, 69.6% of patients took non-prescription drugs for their 
IBS-C (32.4% laxatives and 19.6% herbal medicine) and 27.5% of patients sought 
complementary therapies. Overall, improvement in symptom severity (IBS-SSS 
total score±SD) was observed between baseline (288.3±78.8) and the 6-month visit 
(228.1±9.1). ConClusions: Patients with moderate-to-severe IBS-C often remain 
undiagnosed for over 10 years and undergo a variety of diagnostic procedures. 
Chronic comorbidities are frequent. Despite a high use of both prescription and 
non-prescription drugs, mean symptom severity did improve but remained “mod-
erate” overall.
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objeCtives: Assess clinical characteristics and patterns of care among patients 
with G1 Hepatitis C virus (HCV) in EU. Methods: A multi-center retrospective 
chart-review study of HCV patients was conducted in the EU (France/Germany/
Italy/Spain/UK) in 4Q2014 to collect de-identified data on diagnosis, clinical 
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objeCtives: To assess the impact of irritable bowel syndrome with constipation 
(IBS-C) and chronic constipation (CC) on health-related quality of life (HRQOL), 
work and daily activity among US commercially-insured patients. Methods: 
Consenting survey-eligible patients ≥ 18 years identified from the HealthCore 
Integrated Research Database completed a cross-sectional survey. IBS-C cases that 
had ≥ 1 IBS claim and either ≥ 2 constipation claims or ≥ 1 constipation claim and 
≥ 1 constipation-related pharmacy claim and CC cases that had ≥ 2 constipation 
claims ≥ 90 days apart or ≥ 1 constipation claim and ≥ 1 constipation-related phar-
macy claim ≥ 90 days apart were included. Controls were matched on age, gender, 
region, plan type and insurance status. Only cases meeting and controls not meeting 
modified Rome III criteria completed the survey. Short Form-12 v2 physical com-
ponent summary (PCS) and mental component summary (MCS) [range: 0–100; US 
normative mean= 50]) and EuroQol-5D (EQ-5D; range: 0= death to 1= perfect health) 
assessed HRQOL. Work Productivity and Activity Impairment Questionnaire (General 
Health version) assessed absenteeism, presenteeism and daily activities (higher 
percentages indicate greater impairment). Indirect costs were calculated based on 
overall work productivity loss (absenteeism+presenteeism) using the human capi-
tal method. Results: Among 354 respondents (177 IBS-C/CC cases, 177 controls; 
mean age 46±15 years; 86% female; 66% employed), mean PCS and MCS scores 
were lower for cases versus controls (mean differences: 8.9 (p< 0.01), 6.8 (p< 0.01), 
respectively). EQ-5D mean utility score was lower among cases versus controls 
(0.7 versus 0.9; p< 0.01). Cases also had greater overall work productivity loss (28% 
versus 12%; p< 0.01) and activity impairment (39% versus 15%; p< 0.01). Estimated 
indirect costs were $108 higher per employed respondent/week for cases versus 
controls (p< 0.01). ConClusions: IBS-C/CC patients reported lower HRQOL and 
greater impairments in work and daily activity compared with matched controls. 
Treatments that effectively manage IBS-C/CC symptoms may improve these out-
comes in IBS-C/CC patients.
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objeCtives: Liver diseases (LDs) can reduce health-related quality-of-life (HRQoL), 
with an important impact on the burden of LDs. Our aim was to analyze the 
impact of the major LDs on EQ-5D Visual Analogue Scale (VAS) and utility-index 
(UI) through different regression models, using HRQoL of the general population 
as a reference. Methods: HRQoL data were measured using the EQ-5D-3L in a 
sample of patients with 9 major LDs enrolled during 2011-2012 in a multicenter 
study conducted in the most populated region of Italy, Lombardy. Such data 
were added to those recorded in 2013 on a representative sample of Lombardy 
general population. Relationships between the outcomes of interest (VAS and UI) 
and LDs were explored through ordinary least squares (OLS) and Tobit regression, 
that accounts for ceiling effect, adjusting for age and gender. Goodness-of-fit was 
assessed through R2 (OLS) and pseudo-R2(Tobit). Results: The sample included 
9,817 subjects (3,017 with LDs). OLS and Tobit regressions performed similarly on 
VAS (R2:0.13,pseudo-R2:0.12) and estimated the largest and significant HRQoL reduc-
tion in patients with decompensated cirrhosis (DC), followed by those with autoim-
mune hepatitis (AIH) and hepatocellular carcinoma (HCC). As for UI, the Tobit model 
performed better than OLS regression (R2:0.11,pseudo-R2:0.15), with the highest 
decrease estimated in patients with DC, followed by those with HCC and compen-
sated cirrhosis. ConClusions: The Tobit model performed slightly better than OLS 
regression on the UI, but not on VAS, maybe due to a stronger ceiling effect in UI. 
This distributional difference mirrors different data-generation mechanisms: UI is 
derived from the EQ-5D-3L domains, while VAS is reported by patients. Therefore, 
VAS and UI might capture different aspects of HRQoL, as supported by our results, 
that show how the same LD can be differently associated with VAS and UI (e.g.: AIH 
seemed to have an impact on VAS only, while HCC on UI only).
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objeCtives: The number of patients over 19 years with registered inflammable 
bowel disease which has non-infectious origin is duplicated in the last 16 years (KSH 
2013). Our aim is to get a picture about the different dimensions of life quality in the 
course of the chronic disease. Methods: Cross-sectional, quantitative examina-
tion was carried out between 15.07.2014 and 31.12.2014 at the Clinical Centre of the 
University of Pécs. Patients with M Crohn and ulcerative colitis between the age of 
18 and 46 were selected with non-randomized, convenience sampling method. For 
data collection we used standard questionnaires (Illness Intrusiveness Rating Scale, 
IBDQ, Coloplast life quality questionnaire) and questions about demographic data 
(N= 103). We used Microsoft Excel 2013 software to carry out descriptive statistics, 
two-sample t-test and χ 2- test (p< 0.05). Results: The age of the patients were 
between 31.03±8.18. Illness Intrusiveness Rating Scale (the effect of the disease 
on role efficiency) was evaluated more unfavourable by the patients with ulcera-
tive colitis (p< 0.05). Average life quality is not affected by gender (p= 0.21), marital 
status (p= 0.15), te type of the disease (p= 0.77), and employment status (p= 0.75). 
